---
figid: PMC6835776__pharmaceutics-11-00493-g003
figlink: /pmc/articles/PMC6835776/figure/pharmaceutics-11-00493-f003/
number: F3
caption: 'Schematic diagram of the proposed effects of ZnO nanocomposites on antigen-presenting
  cells and their potential role in inducing T cell responses in draining lymph node.
  Various forms of ZnO nanocomposites (e.g., ZnO NPs and NWs) can stimulate inflammatory
  responses in antigen-presenting cells via TLR recognition or direct endocytosis/phagocytosis,
  which subsequently initiates immune signaling cascades. TLR stimulation by ZnO nanocomposites
  can upregulate downstream molecules IRAK and TRAF, and enhance subsequent MAPK pathways.
  Then, the inhibitor of NFκB, IκB, is degraded and NFκB is activated accordingly.
  Endocytosed ZnO nanocomposites transported into the acidic lysosomes dissociate
  into Zn2+ ions and ionic form of zinc disrupts oxidative balance, increasing ROS
  generation. Ultimately, upregulation of pro-inflammatory signaling pathway and ROS
  generation enhance the production of pro-inflammatory cytokines and chemokines,
  and increase the surface expression of co-stimulatory and antigen presenting molecules.
  Stimulated antigen presenting cells migrate into draining lymph node and prime naïve
  CD4 and CD8 T cells into effector T cells, which can initiate both humoral and cell-mediated
  immune responses against specific antigen associated with ZnO nanocomposites. A
  representative example of anti-cancer immunity induced by ZnO nanocomposites coated
  with a tumor antigen, carcinoembryonic antigen (CEA), is presented in the right
  panel (Reproduced from Sharma et al. [] which is licensed under a Creative Commons
  Attribution-(CC BY 4.0) International License (https://creativecommons.org/licenses/by-nc/3.0/).).
  NP: nanoparticle, NW: nanowire, TLR: Toll-like receptor, MyD88: myeloid differentiation
  primary response protein-88, IRAK: IL-1 receptor associated kinase, TRAF: TNFR-associated
  factor, MAPK: mitogen-activated protein kinase pathway, NFκB: nuclear factor κ chain
  enhancer of activated B cells, IκB: inhibitor of κB, AP-1: activator protein 1,
  ROS: reactive oxygen species.'
pmcid: PMC6835776
papertitle: Application of ZnO-Based Nanocomposites for Vaccines and Cancer Immunotherapy.
reftext: Prashant Sharma, et al. Pharmaceutics. 2019 Oct;11(10):493.
pmc_ranked_result_index: '120654'
pathway_score: 0.7213957
filename: pharmaceutics-11-00493-g003.jpg
figtitle: Proposed effects of ZnO nanocomposites on antigen-presenting cells and their
  potential role in inducing T cell responses in draining lymph node
year: '2019'
organisms: Homo sapiens
ndex: 010ef1f5-df22-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6835776__pharmaceutics-11-00493-g003.html
  '@type': Dataset
  description: 'Schematic diagram of the proposed effects of ZnO nanocomposites on
    antigen-presenting cells and their potential role in inducing T cell responses
    in draining lymph node. Various forms of ZnO nanocomposites (e.g., ZnO NPs and
    NWs) can stimulate inflammatory responses in antigen-presenting cells via TLR
    recognition or direct endocytosis/phagocytosis, which subsequently initiates immune
    signaling cascades. TLR stimulation by ZnO nanocomposites can upregulate downstream
    molecules IRAK and TRAF, and enhance subsequent MAPK pathways. Then, the inhibitor
    of NFκB, IκB, is degraded and NFκB is activated accordingly. Endocytosed ZnO nanocomposites
    transported into the acidic lysosomes dissociate into Zn2+ ions and ionic form
    of zinc disrupts oxidative balance, increasing ROS generation. Ultimately, upregulation
    of pro-inflammatory signaling pathway and ROS generation enhance the production
    of pro-inflammatory cytokines and chemokines, and increase the surface expression
    of co-stimulatory and antigen presenting molecules. Stimulated antigen presenting
    cells migrate into draining lymph node and prime naïve CD4 and CD8 T cells into
    effector T cells, which can initiate both humoral and cell-mediated immune responses
    against specific antigen associated with ZnO nanocomposites. A representative
    example of anti-cancer immunity induced by ZnO nanocomposites coated with a tumor
    antigen, carcinoembryonic antigen (CEA), is presented in the right panel (Reproduced
    from Sharma et al. [] which is licensed under a Creative Commons Attribution-(CC
    BY 4.0) International License (https://creativecommons.org/licenses/by-nc/3.0/).).
    NP: nanoparticle, NW: nanowire, TLR: Toll-like receptor, MyD88: myeloid differentiation
    primary response protein-88, IRAK: IL-1 receptor associated kinase, TRAF: TNFR-associated
    factor, MAPK: mitogen-activated protein kinase pathway, NFκB: nuclear factor κ
    chain enhancer of activated B cells, IκB: inhibitor of κB, AP-1: activator protein
    1, ROS: reactive oxygen species.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FOS
  - FOSB
  - FOSL2
  - JUN
  - JUNB
  - JUND
  - FOSL1
  - CD4
  - CD8A
  - CD8B
  - CEACAM5
  - CXCL13
  - CXCL1
  - CXCL2
  - CXCL3
  - CXCL8
  - CXCL10
  - CXCL9
  - PF4
  - PPBP
  - CXCL6
  - CXCL11
  - CXCL5
  - CXCL12
  - CXCL14
  - IFNG
  - IRAK1
  - MAPK14
  - MAPK1
  - MAPK3
  - MAPK8
  - MAPK11
  - MAPK9
  - MAPK10
  - MAPK13
  - MAPK12
  - MYD88
  - NFKB1
  - NFKB2
  - REL
  - RELA
  - RELB
  - NPS
  - TLR6
  - TLR7
  - TLR8
  - TLR9
  - TLR1
  - TLR2
  - TLR3
  - TLR4
  - TLR5
  - TLR10
  - TRAF1
  - TRAF2
  - TRAF3
  - TRAF5
  - TRAF6
  - TRAF7
  - TRAF4
  - ZnO
  - Zn
  - PLLA-Zno
  - PLLA
  - PLLA-ZnOCEA
  - cancer
  - tumor
genes:
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: FOS
  entrez: '2353'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: FOSB
  entrez: '2354'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: FOSL2
  entrez: '2355'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: JUN
  entrez: '3725'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: JUNB
  entrez: '3726'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: JUND
  entrez: '3727'
- word: AP-1
  symbol: AP1
  source: bioentities_symbol
  hgnc_symbol: FOSL1
  entrez: '8061'
- word: CD4
  symbol: CD4
  source: hgnc_symbol
  hgnc_symbol: CD4
  entrez: '920'
- word: CD8
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8A
  entrez: '925'
- word: CD8
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8B
  entrez: '926'
- word: CEA-
  symbol: CEA
  source: hgnc_prev_symbol
  hgnc_symbol: CEACAM5
  entrez: '1048'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL13
  entrez: '10563'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL1
  entrez: '2919'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL2
  entrez: '2920'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL3
  entrez: '2921'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL8
  entrez: '3576'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL10
  entrez: '3627'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL9
  entrez: '4283'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: PF4
  entrez: '5196'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: PPBP
  entrez: '5473'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL6
  entrez: '6372'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL11
  entrez: '6373'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL5
  entrez: '6374'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL12
  entrez: '6387'
- word: Chemokines
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL14
  entrez: '9547'
- word: IFNy-
  symbol: IFNG
  source: hgnc_symbol
  hgnc_symbol: IFNG
  entrez: '3458'
- word: IRAK
  symbol: IRAK
  source: hgnc_alias_symbol
  hgnc_symbol: IRAK1
  entrez: '3654'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: MYD88
  symbol: MYD88
  source: hgnc_symbol
  hgnc_symbol: MYD88
  entrez: '4615'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB2
  entrez: '4791'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: REL
  entrez: '5966'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELA
  entrez: '5970'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELB
  entrez: '5971'
- word: NPs
  symbol: NPS
  source: hgnc_symbol
  hgnc_symbol: NPS
  entrez: '594857'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR6
  entrez: '10333'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR7
  entrez: '51284'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR8
  entrez: '51311'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR9
  entrez: '54106'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR1
  entrez: '7096'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR2
  entrez: '7097'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR3
  entrez: '7098'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR4
  entrez: '7099'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR5
  entrez: '7100'
- word: TLR
  symbol: TLR
  source: bioentities_symbol
  hgnc_symbol: TLR10
  entrez: '81793'
- word: TRAF
  symbol: TRAF
  source: bioentities_symbol
  hgnc_symbol: TRAF1
  entrez: '7185'
- word: TRAF
  symbol: TRAF
  source: bioentities_symbol
  hgnc_symbol: TRAF2
  entrez: '7186'
- word: TRAF
  symbol: TRAF
  source: bioentities_symbol
  hgnc_symbol: TRAF3
  entrez: '7187'
- word: TRAF
  symbol: TRAF
  source: bioentities_symbol
  hgnc_symbol: TRAF5
  entrez: '7188'
- word: TRAF
  symbol: TRAF
  source: bioentities_symbol
  hgnc_symbol: TRAF6
  entrez: '7189'
- word: TRAF
  symbol: TRAF
  source: bioentities_symbol
  hgnc_symbol: TRAF7
  entrez: '84231'
- word: TRAF
  symbol: TRAF
  source: bioentities_symbol
  hgnc_symbol: TRAF4
  entrez: '9618'
chemicals:
- word: ZnO
  source: MESH
  identifier: D015032
- word: Zn
  source: MESH
  identifier: D015032
- word: PLLA-Zno
  source: MESH
  identifier: C445939
- word: PLLA
  source: MESH
  identifier: C445939
- word: PLLA-ZnOCEA
  source: MESH
  identifier: D015032
diseases:
- word: cancer
  source: MESH
  identifier: D009369
- word: tumor
  source: MESH
  identifier: D009369
figid_alias: PMC6835776__F3
redirect_from: /figures/PMC6835776__F3
figtype: Figure
---
